Item 7.01. Regulation FD Disclosure.

During February 12-14, 2013, Sucampo Pharmaceuticals, Inc. ("Company") will make corporate update presentations at one-on-one meetings with analysts and investors in New York City, NY. On February 12, 2013, the Company will make a corporate update presentation via webcast at an investor conference in New York City, NY at the 15th Annual BIO CEO & Investor Conference. On February 14, 2013, the Company will make a corporate update presentation via webcast at an investor conference in New York City, NY at the Leerink Swann Global Healthcare Conference 2013. All meetings will include modifications to three slides from those slides filed on Form 8K dated January 7, 2013. The additional slides are being furnished as Exhibit 99.1 to this Current Report on Form 8-K.

The information in this Item 7.01 and Exhibit 99.1 to this Form 8-K shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 (the "Exchange Act") or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

Item 9.01 Financial Statements and Exhibits

(d) Exhibits

99.1 The modifications of the five slides to the corporate update presentation slides dated February 12, 2013.

---